anti-PD-L1

What now for low-cost PD-(L)1 competition?
EP Vantage
Fri, 03/18/22 - 10:25 am
FDA
anti-PD-L1
Innovent
Eli Lilly
Pfizer reveals its PD-1 secret
EP Vantage
Fri, 02/5/21 - 10:42 am
Pfizer
anti-PD-L1
sasanlimab
Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1
Endpoints
Wed, 11/13/19 - 10:03 am
China
BeiGene
Amgen
tislelizumab
anti-PD-L1
FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market
BioCentury
Sat, 04/6/19 - 01:41 pm
Richard Pazdur
FDA
China
anti-PD-L1
Using Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy
Fierce Biotech
Wed, 02/20/19 - 08:00 pm
cancer
Cedars Sinai
Bristol-Myers Squibb
Sprycel
anti-PD-L1
After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market
Endpoints
Sat, 07/28/18 - 01:02 pm
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
anti-PD-L1
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Endpoints
Tue, 05/29/18 - 08:54 am
Roche
Tecentriq
anti-PD-L1
non-squamous non-small cell lung cancer
Merck
Bristol-Myers Squibb
Boehringer, BeiGene enter manufacturing pact for PD-1 drug
Biopharma Dive
Thu, 01/11/18 - 11:54 pm
Boehringer Ingelheim
BeiGene
tislelizumab
anti-PD-L1
drug manufacturing
Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?
Endpoints
Wed, 12/13/17 - 09:44 am
Regeneron
Sanofi
anti-PD-L1
cemiplimab
advanced cutaneous squamous cell carcinoma
Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study
Endpoints
Tue, 11/28/17 - 10:11 am
Pfizer
Merck KGaA
Bavencio
anti-PD-L1
gastric cancer
An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem
Endpoints
Sun, 11/12/17 - 11:09 am
anti-PD-L1
drug development
Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Endpoints
Fri, 09/8/17 - 09:38 am
Sanofi
Regeneron
fast track
breakthrough status
cemiplimab
anti-PD-L1
Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table
Endpoints
Thu, 07/6/17 - 09:33 am
Celgene
anti-PD-L1
BeiGene
Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?
Endpoints
Fri, 06/9/17 - 11:13 am
Merck
anti-PD-L1
Keytruda
MK-1308
Bristol-Myers Squibb
AstraZeneca delays PD-L1 data in rejig of phase 3 program
Fierce Biotech
Tue, 01/17/17 - 10:02 am
AstraZeneca
anti-PD-L1
clinical trials
tremelimumab
durvalumab
Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?
Endpoints
Sun, 12/11/16 - 11:57 am
AstraZeneca
durvalumab
anti-PD-L1
bladder cancer
FDA Grants Merck Priority Review for Keytruda Drug (MRK)
Investopedia
Mon, 11/28/16 - 09:56 am
FDA
priority review
Keytruda
Merck
non-small cell lung cancer
anti-PD-L1
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
Market Realist
Mon, 11/21/16 - 11:39 am
AstraZeneca
anti-PD-L1
durvalumab
Opdivo
Keytruda
Tecentriq
Bristol-Myers Squibb
Roche
Merck
New anti-PD1 drugs overpriced, ICER says
BioPharma Dive
Thu, 10/6/16 - 09:37 am
drug pricing
ICER
anti-PD-L1
Opdivo
Keytruda
Bristol-Myers Squibb
Merck
Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data
Seeking Alpha
Sun, 09/18/16 - 09:54 am
Amgen
biosimilars
AstraZeneca
anti-PD-L1
ABP 501
Humira
durvalumab

Pages